6:16 PM
 | 
Dec 19, 2011
 |  BC Extra  |  Financial News

PDL expects decline in 4Q revenues

PDL BioPharma Inc. (NASDAQ:PDLI) said it expects 4Q11 revenues of $72 million, down 5% from $76 million in 4Q10 and below the Street's estimate of $82.5 million. PDL attributed the decline in part to reduced royalties from third quarter...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >